Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ABS-201 in Adult Participants With and Without Androgenetic Alopecia
In the register
The register attaches this trial to ABS-201 (Absci), currently at “Phase 1/2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 1/2
- Sponsor
- Absci Pty Ltd.
- Participants (registry)
- 227
- Start
- December 2025
- Primary completion
- July 2028 (planned)
- Study completion
- July 2028 (planned)
- Last registry update
- September 2026
- Countries
- Australia
Conditions studied: Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female
Interventions: SAD IV Dose 1 - 150mg ABS201 IV Single Dose, Placebo IV, ABS-201 SC Multiple Doses, Placebo SC Injection
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.